Patients with COVID-19 MI presented a more severe clinical state on admission (assessed by a lower systolic blood pressure, higher respiratory rate, higher GRACE score) in comparison with the non-COVID-19 MI group; however, there were no significant differences in the frequency of STEMI/NSTEMI, admission values of high sensitivity cardiac troponin (hs cTn), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and LVEF between groups (Table 2). This evidence concerns the gene MAP3K14 and myocardial infarction.